Epcoritamab DLBCL treatment gains momentum as AbbVie and Genmab report a 51 percent reduction in progression or death risk.
In an interaction with Thiruamuthan, Assistant Editor at India Pharma Outlook magazine, Dr. Anudeep Sandhu, Director, Medical and Clinical Affairs, Terumo India, discusses how MedTech companies can strengthen clinical adoption by aligning innovation
The latest updates highlight three strong mid-stage results in the pharma pipeline, as Eli Lilly, Merck, and AbbVie advance promising therapies toward Phase 3 trials.
Akums gets DCGI approval for 0.5 mg Colchicine tablets, marking a first-time-in-India milestone in preventive cardiology and cardiovascular care.
Diabetes care advances with new insulin, a new trial, and fresh funding, expanding treatment options for type 2 diabetes.
EU regulators extend single-inhaler triple therapy access to teenagers with asthma, giving patients aged 12 and older a new maintenance option.
Amgen eyes a wide-open Sjogren's disease market after dazodalibep delivers positive late-stage trial results and meets its primary goal.
CagriSema's latest results highlight how obesity drug development is shifting toward multi-mechanism therapies combining complementary biological pathways.
In an exclusive conversation with Thiruamuthan, Assistant Editor at India Pharma Outlook magazine, Anil Suri, Chief Commercial Officer, Sahajanand Medical Technologies, explores how MedTech companies can build evidence beyond regulatory requirements,
Caplyta opens a new chapter for J&J in bipolar treatment as late-stage data support its potential expansion into bipolar mania.
.jpg)
, CDSCO.jpg)